Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
A K Kannan
Observed names:
Arun K Kannan,
Arun K. Kannan
Institution:
Johnson & Johnson (United States)
Observed institution:
Johnson & Johnson (United States)
OpenAlex ID:
A5123522387
Multiomic characterisation of the clinical efficacy of guselkumab induction therapy in ulcerative colitis
2026
·
Amy Hart
, Sunandini Sridhar
, et al.
·
BMJ Open Gastroenterology
·
3
PDF
OP29 Icotrokinra, the first targeted oral peptide that selectively blocks the interleukin-23 receptor, reduces systemic and tissue inflammatory burden in Ulcerative Colitis: Results from the ANTHEM-UC study
2026
·
E Louis
, V Jairath
, et al.
·
Journal of Crohn s and Colitis
·
1
Phase 2 Trial of Icotrokinra for Patients with Ulcerative Colitis
2026
·
Maria T. Abreu
, Britta Siegmund
, et al.
·
New England Journal of Medicine
Show more works
View as search
Works count:
3
Citation count:
4
H-index:
1
I10-index:
Year
Topic
Type
